Calcilytix Therapeutics, Inc., a BridgeBio company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Calcilytix Therapeutics, Inc., a BridgeBio company sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Calcilytix Therapeutics, Inc., a BridgeBio company: 4 sponsored US clinical trials, 1 recruiting.
Calcilytix Therapeutics, Inc., a BridgeBio company sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autosomal Dominant Hypocalcemia, with 1 trials.
Upper-quartile sponsor footprint
Calcilytix Therapeutics, Inc., a BridgeBio company sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT07080385
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
NCT05680818
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
NCT04581629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the Calcilytix Therapeutics, Inc., a BridgeBio company pipeline
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Autosomal Dominant Hypocalcemia (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Calcilytix Therapeutics, Inc., a BridgeBio company: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Calcilytix Therapeutics, Inc., a BridgeBio company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Calcilytix Therapeutics, Inc., a BridgeBio company page
4 registered trials is a research-attention snapshot, not an endorsement of Calcilytix Therapeutics, Inc., a BridgeBio company or any single study.
- 1 of Calcilytix Therapeutics, Inc., a BridgeBio company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Autosomal Dominant Hypocalcemia is the condition Calcilytix Therapeutics, Inc., a BridgeBio company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autosomal Dominant Hypocalcemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Calcilytix Therapeutics, Inc., a BridgeBio company pipeline card: 4 registered trials from official public datasets.Report a data error.